Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.52 | $0 | -$3M |
| 2026 Q1 | -1.61 | $0 | -$3M |
| 2025 Q4 | -1.20 | $0 | -$2M |
| 2025 Q3 | -1.50 | $0 | -$4M |
| 2025 Q2 | -1.53 | $0 | -$3M |
| 2025 Q1 | -3.25 | $0 | -$3M |
| 2024 Q4 |
| -2.60 |
| $0 |
| -$3M |
| 2024 Q3 | -1.74 | $0 | -$4M |